- Conditions
- Chronic Myelogenous Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Severe Aplastic Anemia
- Interventions
- umbilical cord blood (UCB)
- Genetic
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1129–1152
of 1,728
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric, Obesity, Pediatric
- Interventions
- Low Glycemic Index Diet
- Behavioral
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 5
- States / cities
- Hartford, Connecticut • Washington D.C., District of Columbia • Buffalo, New York + 2 more
- Conditions
- Stem Cell Transplantation, Pediatric Cancer, Acute Lymphoblastic Leukemia
- Interventions
- Cognitive rehabilitation program
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies, Ewing Sarcoma, Vomiting in Infants and/or Children, Osteosarcoma
- Interventions
- electroacupuncture therapy, questionnaire administration
- Procedure · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 8 Years to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Corticosteroid, Rapamycin
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 365 Days and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, cyclosporine, methylprednisolone, bone marrow ablation with stem cell support, umbilical cord blood transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 5 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2017
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Non-Hodgkin Lymphoma
- Interventions
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 811 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 168
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 119 more
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, sargramostim, busulfan, etoposide, fludarabine phosphate, prednisone, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection
- Procedure
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, T-cell Adult Acute Lymphoblastic Leukemia
- Interventions
- MLN 9708, Vincristine, Cytarabine, Doxorubicin, Mercaptopurine, Cyclophosphamide, Methotrexate
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 51 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Cancer
- Interventions
- captopril, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorder, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Non-malignant Diseases Requiring Allogeneic HSCT
- Interventions
- IL-2
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Leukemia
- Interventions
- clofarabine, cytarabine, methotrexate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Downey, California • Long Beach, California + 65 more
- Conditions
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia
- Interventions
- Induction Phase, Re-Induction Phase, Post-Remission, Maintenance
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 60 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Orange, California • Detroit, Michigan + 11 more
- Conditions
- Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma in Complete Remission, Mixed Phenotype Acute Leukemia in Complete Remission
- Interventions
- Ixazomib
- Drug
- Lead sponsor
- Ehab L Atallah
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Related Donors Donating PBSC to a Family Member, Healthy Donors, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Interventions
- MGTA-145, Plerixafor
- Biological
- Lead sponsor
- Ensoma
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 8
- States / cities
- Duarte, California • Stanford, California • Atlanta, Georgia + 5 more
- Conditions
- Acute Myeloid Leukemia, Infantile Leukemia (Both AML and ALL), Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, Biphenotypic Leukemia
- Interventions
- Sorafenib, Cytarabine, Clofarabine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 31 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- everolimus, panobinostat, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Duarte, California • Pasadena, California
- Conditions
- Lymphoma
- Interventions
- estramustine phosphate sodium, paclitaxel
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 17
- States / cities
- Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 14 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- JCAR015
- Genetic
- Lead sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Baltimore, Maryland • St Louis, Missouri + 1 more
- Conditions
- B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult, B-ALL
- Interventions
- Blinatumomab Injection
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Leukemia
- Interventions
- Blinatumomab, Oncaspar, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Mercaptopurine, Methotrexate, Vincristine
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 51 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- filgrastim, busulfan, cyclophosphamide, cyclosporine, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 4 Years to 55 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2009
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
- Interventions
- Bortezomib, Vorinostat, Mitoxantrone, Cytarabine, Methotrexate, Hydrocortisone, Peg-L-Asparaginase, Erwinia L-Asparaginase, Dexamethasone, Mercaptopurine, Doxorubicin
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee